# Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients - A Multi Center Chart Review

> **NCT04609319** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 307 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** Dacomitinib

## Key facts

- **NCT ID:** NCT04609319
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-11
- **Primary completion:** 2024-05-28
- **Final completion:** 2024-05-28
- **Target enrollment:** 307 (ACTUAL)
- **Last updated:** 2025-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04609319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04609319, "Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients - A Multi Center Chart Review". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT04609319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*